1.48
-0.05 (-3.27%)
| Penutupan Terdahulu | 1.53 |
| Buka | 1.53 |
| Jumlah Dagangan | 934,631 |
| Purata Dagangan (3B) | 2,183,588 |
| Modal Pasaran | 111,050,712 |
| Harga / Pendapatan (P/E Ke hadapan) | 5.39 |
| Harga / Buku (P/B) | 3.35 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 14 Nov 2025 |
| EPS Cair (TTM) | -0.040 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.77% |
| Nisbah Semasa (MRQ) | 13.90 |
| Aliran Tunai Operasi (OCF TTM) | -54.59 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -26.72 M |
| Pulangan Atas Aset (ROA TTM) | -40.10% |
| Pulangan Atas Ekuiti (ROE TTM) | -38.15% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Eledon Pharmaceuticals, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 3.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.5 |
| Purata | 1.13 |
|
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 1.40% |
| % Dimiliki oleh Institusi | 68.39% |
| Julat 52 Minggu | ||
| Median | 8.00 (440.54%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Guggenheim | 18 Nov 2025 | 8.00 (440.54%) | Beli | 1.54 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |